Sign inJoin waitlistJoin the waitlist

Andrei Iagaru

Program Director, Nuclear Medicine Residency Program (2011 · Stanford Health Care

Credentials: · · ·

History

Nuclear Medicine Residency Program (2011 Residency · Stanford Health Care
Present
Division of Nuclear Medicine and Molecular Imaging - Stanford · Stanford Health Care
Present
Nuclear Medicine & Molecular Imaging Division · Stanford Health Care
Present

Nuclear Medicine
Stanford Health Care
2004–2007
Stanford University Medical Center (2007) CA
2006–2007
Graduate Hospital (Closed) (2004) PA
2000–2004
Facultatea de Medicină a Universității de Medicină și Farmacie Carol Davila
1996–2000

Research

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 433 citations
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
Clinical Cancer Research · 2021 · 317 citations
NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
Journal of the National Comprehensive Cancer Network · 2018 · 272 citations

Sanjiv Gambhir
46 papers
Guido Davidzon
35 papers
EM
Erik Mittra
31 papers · 6 as a resident
Farshad Moradi
25 papers · 2 as a fellow
NH
Negin Hatami
18 papers · 6 as a resident
MJ
Mehran Jamali
17 papers · 3 as a resident
Andrew Quon
16 papers
Hong Song
15 papers · 14 as a resident
Shreyas Vasanawala
13 papers · 7 as a fellow
MG
Michael Goris
12 papers
Andreas Loening
11 papers · 1 as a fellow
Benjamin Franc
11 papers

Grants

Evaluation of Patients with Low-Risk and Intermediate-Risk Prostate Cancer Scheduled for High-Dose Rate Brachytherapy Using 68Ga-RM2 PET, 68Ga-PSMA-11 PET and Multi Parametric MRI
National Cancer Institute · R01
Contact PI · $1.2M · Stanford University
2019–2024
Molecular Imaging Methods for the Detection of Pancreatic Ductal Adenocarcinoma
National Cancer Institute · U01
Contact PI · $4.1M · Stanford University
2017–2023

Clinical trials

Biodistribution & Pharmacokinetic of Position Emission Tomography (PET) Radiopharmaceutical 18F C SNAT4
Principal investigator · Suspended · Phase 1
Stanford University
2024–2026
Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
Principal investigator · Withdrawn · Phase 1
Stanford University
2021–2024
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Principal investigator · Terminated · Phase 2
Andrei Iagaru
2020–2022
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Principal investigator · Completed · Phase 1, Phase 2
Andrei Iagaru
2019–2022